États-Unis · Plateformes & données · MarketBeat

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027

Publié par MarketBeat · États-Unis il y a 1 h

Parabilis Medicines (NASDAQ:PBLS) presented updated interim phase I/II data for investigational beta-catenin/TCF inhibitor zolucatetide in desmoid tumors at the European Society…

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027

À lire aussi

Booking vs. Five Below: Is the Travel Giant or Specialty Retailer the Better Stock to Buy in 2026?

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Trump set to announce plan by Audi to build US factory in Georgia, source says

Myro (MYRO) Price Prediction: 2025, 2026, 2030

Gene Munster Says Apple’s $2,200 iPhone Duo Could Add $8B To FY27 Revenue, Sees 20M Units In Sales Even As Wall Street Expects Only 12M

Market News

Parabilis Highlights 72% Response Rate, Maps Phase III Desmoid Trial for 2027

Partager

À lire aussi

Booking vs. Five Below: Is the Travel Giant or Specialty Retailer the Better Stock to Buy in 2026?

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Trump set to announce plan by Audi to build US factory in Georgia, source says

Myro (MYRO) Price Prediction: 2025, 2026, 2030

Gene Munster Says Apple’s $2,200 iPhone Duo Could Add $8B To FY27 Revenue, Sees 20M Units In Sales Even As Wall Street Expects Only 12M

Market News